Therapeutic use for glycine
AssigneeNovartis Nutrition AG
InventorsHeinz Schneider, Ronald G. Thurman, Nigel Scott Cook
Life of this patent
Estimating the term…
Abstract
Glycine is indicated to prevent or treat acute or chronic graft rejection, optionally in combination with an immunosuppressant or an immunomodulating agent.
Claims4
A method of preventing or treating non TNF-induced transplant rejection in a recipient of organ or tissue transplant, comprising the step of enterally administering to said recipient a therapeutically effective amount of glycine, in free form or in pharmaceutically acceptable salt form.
A method of preventing or treating manifestations of chronic rejection in a recipient of organ or tissue transplant, comprising the step of enterally administering to said recipient a therapeutically effective amount of glycine, in free form or in pharmaceutically acceptable salt form.
Dependencies are inferred from the claim text.